Copyright
©The Author(s) 2019.
World J Gastroenterol. Jul 21, 2019; 25(27): 3484-3502
Published online Jul 21, 2019. doi: 10.3748/wjg.v25.i27.3484
Published online Jul 21, 2019. doi: 10.3748/wjg.v25.i27.3484
Table 4 Studies on the ClinicalTrials.gov registry investigating the role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on high risk patients for preventing peritoneal metastases from colorectal origin
ClinicalTrials.gov ID | Phase | High risk criteria | Control vs Treatment arms |
NCT01226394 ProphyloCHIP trial | Phase III | Complete resection of minimal abdominal synchronous metastases or perforated tumors | Surveillance vs second-look laparotomy with HIPEC (intraperitoneal oxaliplatin and intravenous 5-FU) after primary resection |
NCT02231086 COLOPEC trial | Phase III | T4, N0-2M0 or perforated colon cancer | Adjuvant systemic therapy only vs adjuvant systemic therapy + HIPEC, without resection of target organs |
NCT02974556 PROMENADE trial | Phase III | T3-T4 tumors | Resection of target organs for peritoneal implants, plus HIPEC with oxaliplatin and concomitant i.v., 5-fluorouracil/leucovorin |
NCT02179489 | Phase III | T4M0 and complete resection of minimal abdominal synchronous metastases or perforated tumors | Surgery vs surgery and HIPEC with mitomycin C (without preventive excision of target organs) |
NCT02965248 APEC trial | Phase II | T4NanyM0 and T3-NanyM0 + mucinous or signet ring cells histology | Adjuvant systemic chemotherapy alone (arm A) vs systemic chemo + HIPEC with raltitrexed (arm B) or oxaliplatin (arm C) |
NCT02614534 HIPEC T4 | Phase III | Complete resection of T4a, bNanyM0 | Surgery vs prophylactic HIPEC with mitomycin plus target organs excision |
NCT03413254 COLOPEC-II | Phase III | Complete resection of T4a, bN0-2M0 | Routine follow-up (arm A) vs a second exploratory laparoscopy (arm B) and third exploratory laparoscopy (arm C) if the work-up is negative |
NCT02974556 | Phase III | Complete resection of T3-4NanyM0 | Systemic chemotherapy alone vs CRS/HIPEC with oxaliplatin and systemic therapy |
NCT02758951 | Phase II/III | Complete resection of colorectal tumors with ≤ 50% of signet ring cells. | Upfront CRS-HIPEC alone vs pre/post perioperative systemic chemotherapy and CRS-HIPEC |
NCT02830139 | Phase II | Complete resection of T3-4NanyM0 | CRS + systemic chemotherapy vs CRS + HIPEC with paclitaxel + 5-FU + postoperative chemotherapy |
- Citation: Sánchez-Hidalgo JM, Rodríguez-Ortiz L, Arjona-Sánchez Á, Rufián-Peña S, Casado-Adam Á, Cosano-Álvarez A, Briceño-Delgado J. Colorectal peritoneal metastases: Optimal management review. World J Gastroenterol 2019; 25(27): 3484-3502
- URL: https://www.wjgnet.com/1007-9327/full/v25/i27/3484.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i27.3484